




Treprostinil

Revised: February 7, 2019.

CASRN: 81846-19-7



Drug Levels and Effects

Summary of Use during Lactation

One patient taking treprostinil breastfed her infant for one year without any complications. However, until more data are available, treprostinil should only be used with careful monitoring during breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

A woman developed pulmonary artery hypertension and was treated with intravenous treprostinil beginning at 32 weeks of gestation and titrated up to 26 ng/kg/min. The dose was nearly doubled postpartum because of worsening symptoms. She breastfed (extent not stated) her infant for one year with no apparent drug-related problems, although there was concern for obesity at 6 months of age. The infant was healthy and developing normally at 2 years of age.[1]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Franco V, Mueller J, Daniels CJ. Is the use of remodulin safe for pregnant and breastfeeding patients with pulmonary arterial hypertension (PAH)? A case report. *J Heart Lung Transplant*. 2012;31 (4 Suppl):S71. Abstract 188. DOI: [10.1016/j.healun.2012.01.862](https://doi.org/10.1016/j.healun.2012.01.862).

Substance Identification

Substance Name

Treprostinil

CAS Registry Number

81846-19-7

Drug Class

Breast Feeding

Lactation

Antihypertensive Agents

Prostaglandins